SI2177536T1 - Protitelesa proti amiloidnemu peptidu beta - Google Patents
Protitelesa proti amiloidnemu peptidu betaInfo
- Publication number
- SI2177536T1 SI2177536T1 SI200731503T SI200731503T SI2177536T1 SI 2177536 T1 SI2177536 T1 SI 2177536T1 SI 200731503 T SI200731503 T SI 200731503T SI 200731503 T SI200731503 T SI 200731503T SI 2177536 T1 SI2177536 T1 SI 2177536T1
- Authority
- SI
- Slovenia
- Prior art keywords
- antibodies against
- beta peptide
- against amyloid
- amyloid
- peptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US78758806P | 2006-03-30 | 2006-03-30 | |
EP09178407.4A EP2177536B1 (en) | 2006-03-30 | 2007-03-27 | Antibodies against amyloid-beta peptide |
Publications (1)
Publication Number | Publication Date |
---|---|
SI2177536T1 true SI2177536T1 (sl) | 2014-09-30 |
Family
ID=38284050
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200731503T SI2177536T1 (sl) | 2006-03-30 | 2007-03-27 | Protitelesa proti amiloidnemu peptidu beta |
SI200730173T SI1996621T1 (sl) | 2006-03-30 | 2007-03-27 | Protitelesa proti amiloidnemu peptidu beta |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SI200730173T SI1996621T1 (sl) | 2006-03-30 | 2007-03-27 | Protitelesa proti amiloidnemu peptidu beta |
Country Status (33)
Country | Link |
---|---|
US (3) | US8227576B2 (sl) |
EP (2) | EP2177536B1 (sl) |
JP (1) | JP5103466B2 (sl) |
KR (2) | KR20120093400A (sl) |
CN (2) | CN101415729B (sl) |
AR (1) | AR060332A1 (sl) |
AT (1) | ATE451392T1 (sl) |
AU (1) | AU2007233831B2 (sl) |
BR (1) | BRPI0709246A2 (sl) |
CA (1) | CA2647808C (sl) |
CR (1) | CR10347A (sl) |
CY (1) | CY1109877T1 (sl) |
DE (1) | DE602007003703D1 (sl) |
DK (2) | DK2177536T3 (sl) |
EA (1) | EA015654B9 (sl) |
ES (2) | ES2338179T3 (sl) |
HK (2) | HK1138015A1 (sl) |
HR (2) | HRP20100115T1 (sl) |
IL (1) | IL193695A (sl) |
JO (1) | JO2576B1 (sl) |
MA (1) | MA30337B1 (sl) |
MX (1) | MX2008012483A (sl) |
MY (1) | MY149630A (sl) |
NO (1) | NO20083793L (sl) |
NZ (1) | NZ571038A (sl) |
PE (1) | PE20080181A1 (sl) |
PL (2) | PL2177536T3 (sl) |
PT (2) | PT1996621E (sl) |
SI (2) | SI2177536T1 (sl) |
TW (1) | TWI385179B (sl) |
UA (1) | UA94734C2 (sl) |
WO (1) | WO2007113172A2 (sl) |
ZA (1) | ZA200807911B (sl) |
Families Citing this family (62)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080050367A1 (en) | 1998-04-07 | 2008-02-28 | Guriq Basi | Humanized antibodies that recognize beta amyloid peptide |
TWI239847B (en) | 1997-12-02 | 2005-09-21 | Elan Pharm Inc | N-terminal fragment of Abeta peptide and an adjuvant for preventing and treating amyloidogenic disease |
US9221867B2 (en) | 2003-01-06 | 2015-12-29 | Angiochem Inc. | Method for transporting a compound across the blood-brain barrier |
DE10303974A1 (de) | 2003-01-31 | 2004-08-05 | Abbott Gmbh & Co. Kg | Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung |
CA2590337C (en) | 2004-12-15 | 2017-07-11 | Neuralab Limited | Humanized amyloid beta antibodies for use in improving cognition |
AU2006208226A1 (en) | 2005-01-24 | 2006-08-03 | Amgen Inc. | Humanized anti-amyloid antibody |
US8691224B2 (en) | 2005-11-30 | 2014-04-08 | Abbvie Inc. | Anti-Aβ globulomer 5F7 antibodies |
KR20180058863A (ko) | 2005-11-30 | 2018-06-01 | 애브비 인코포레이티드 | 아밀로이드 베타 단백질에 대한 모노클로날 항체 및 이의 용도 |
WO2009017467A1 (en) * | 2007-07-27 | 2009-02-05 | Elan Pharma International Limited | Treatment of amyloidogenic diseases |
US8784810B2 (en) | 2006-04-18 | 2014-07-22 | Janssen Alzheimer Immunotherapy | Treatment of amyloidogenic diseases |
PL2046833T3 (pl) * | 2006-07-14 | 2014-01-31 | Ac Immune Sa | Humanizowane przeciwciało przeciw amyloidowi beta |
US8455626B2 (en) | 2006-11-30 | 2013-06-04 | Abbott Laboratories | Aβ conformer selective anti-aβ globulomer monoclonal antibodies |
US20100311767A1 (en) | 2007-02-27 | 2010-12-09 | Abbott Gmbh & Co. Kg | Method for the treatment of amyloidoses |
US7931899B2 (en) | 2007-05-14 | 2011-04-26 | Medtronic, Inc | Humanized anti-amyloid beta antibodies |
US8323654B2 (en) | 2007-05-14 | 2012-12-04 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
US9365634B2 (en) | 2007-05-29 | 2016-06-14 | Angiochem Inc. | Aprotinin-like polypeptides for delivering agents conjugated thereto to tissues |
US8613923B2 (en) | 2007-06-12 | 2013-12-24 | Ac Immune S.A. | Monoclonal antibody |
US8048420B2 (en) | 2007-06-12 | 2011-11-01 | Ac Immune S.A. | Monoclonal antibody |
CA2695484C (en) * | 2007-08-20 | 2018-05-01 | Glaxo Group Limited | Production method of therapeutic proteins based on codon adaptation |
GB0718737D0 (en) * | 2007-09-25 | 2007-11-07 | Glaxo Group Ltd | Antibodies |
CA2701788C (en) * | 2007-10-05 | 2017-06-13 | Genentech, Inc. | Humanized beta-amyloid antibody for treating ocular diseases |
SI2238166T1 (sl) | 2007-10-05 | 2014-03-31 | Genentech, Inc. | Uporaba protitelesa proti amiloidu beta pri očesnih bolezni |
MX2010003622A (es) * | 2007-10-12 | 2010-04-14 | Hoffmann La Roche | Expresion proteinica a partir de acidos nucleicos multiples. |
JO3076B1 (ar) | 2007-10-17 | 2017-03-15 | Janssen Alzheimer Immunotherap | نظم العلاج المناعي المعتمد على حالة apoe |
EP2586797A3 (en) * | 2007-11-27 | 2013-07-24 | Medtronic, Inc. | Humanized anti-amyloid beta antibodies |
KR101629365B1 (ko) * | 2007-12-11 | 2016-06-14 | 글락소 그룹 리미티드 | 항원 결합성 단백질 |
US8414893B2 (en) | 2007-12-21 | 2013-04-09 | Amgen Inc. | Anti-amyloid antibodies and uses thereof |
TW201006495A (en) | 2008-05-06 | 2010-02-16 | Glaxo Group Ltd | Encapsulation of biologically active agents |
AU2009304560A1 (en) | 2008-10-15 | 2010-04-22 | Angiochem Inc. | Conjugates of GLP-1 agonists and uses thereof |
US9067981B1 (en) | 2008-10-30 | 2015-06-30 | Janssen Sciences Ireland Uc | Hybrid amyloid-beta antibodies |
CA2745524C (en) | 2008-12-05 | 2020-06-09 | Angiochem Inc. | Conjugates of neurotensin or neurotensin analogs and uses thereof |
AU2010239069B2 (en) | 2009-04-20 | 2015-05-14 | Angiochem Inc | Treatment of ovarian cancer using an anticancer agent conjugated to an Angiopep-2 analog |
EP2448965A4 (en) * | 2009-07-02 | 2015-02-11 | Angiochem Inc | MULTIMEPEPTID CONJUGATES AND ITS USES |
EA022007B1 (ru) | 2009-09-11 | 2015-10-30 | Пробиодруг Аг | Гетероциклические производные в качестве ингибиторов глутаминилциклазы |
EP2308897A1 (en) * | 2009-10-09 | 2011-04-13 | Pierre Fabre Medicament | Chimeric antibodies specific for CD151 and use thereof in the treatment of cancer |
JP5826194B2 (ja) | 2010-03-03 | 2015-12-02 | アブリンクス ナームローゼ フェンノートシャップ | 二パラトープ性a−ベータ結合ポリペプチド |
US8987419B2 (en) | 2010-04-15 | 2015-03-24 | AbbVie Deutschland GmbH & Co. KG | Amyloid-beta binding proteins |
WO2011149461A1 (en) * | 2010-05-27 | 2011-12-01 | Medtronic, Inc. | Anti-amyloid beta antibodies conjugated to sialic acid-containing molecules |
MY164579A (en) | 2010-07-30 | 2018-01-15 | Ac Immune Sa | Safe and functional humanized antibodies |
CN103298833B (zh) | 2010-08-14 | 2015-12-16 | Abbvie公司 | β淀粉样蛋白结合蛋白 |
NZ724348A (en) * | 2010-11-30 | 2019-12-20 | Genentech Inc | Low affinity blood brain barrier receptor antibodies and uses therefor |
CA2826286C (en) | 2011-01-31 | 2021-09-21 | Intellect Neurosciences Inc. | Treatment of tauopathies |
SG194510A1 (en) | 2011-04-22 | 2013-12-30 | Emergent Product Dev Seattle | Prostate-specific membrane antigen binding proteins and related compositionsand methods |
GB201113570D0 (en) * | 2011-08-05 | 2011-09-21 | Glaxosmithkline Biolog Sa | Vaccine |
MY181743A (en) | 2012-05-21 | 2021-01-06 | Genentech Inc | Methods for improving safety of blood-brain barrier transport |
RU2509155C1 (ru) * | 2012-10-25 | 2014-03-10 | Федеральное государственное бюджетное учреждение науки Институт биохимии им. А.Н. Баха Российской академии наук | Способ детекции белков в амилоидном состоянии и набор для детекции белков в амилоидном состоянии |
WO2014203188A2 (en) | 2013-06-19 | 2014-12-24 | Glaxosmithkline Intellectual Property (No.2) Limited | Novel assay |
CN104558172A (zh) * | 2015-01-04 | 2015-04-29 | 东南大学 | 一种针对β淀粉样蛋白的单域重链纳米抗体及其应用 |
CN107921143B (zh) | 2015-06-15 | 2021-11-19 | 安吉奥开米公司 | 用于治疗软脑膜癌病的方法 |
JP7002446B2 (ja) | 2015-09-21 | 2022-03-04 | アプティーボ リサーチ アンド デベロップメント エルエルシー | Cd3結合ポリペプチド |
WO2017072090A1 (en) * | 2015-10-27 | 2017-05-04 | Glaxosmithkline Intellectual Property Development Limited | Combination therapy |
EP3624842A4 (en) * | 2017-06-29 | 2021-04-07 | The Trustees Of Columbia University In The City Of New York | CHIMERA ANTIBODIES FOR TREATMENT OF AMYLOID DEPOSITION DISEASES |
US11382974B2 (en) | 2017-08-01 | 2022-07-12 | The Trustees Of Columbia University In The City Of New York | Methods and compositions for treatment of amyloid deposition diseases |
ES2812698T3 (es) | 2017-09-29 | 2021-03-18 | Probiodrug Ag | Inhibidores de glutaminil ciclasa |
AU2019304384A1 (en) * | 2018-07-17 | 2021-01-28 | Jiangsu Hengrui Medicine Co., Ltd. | Anti-abeta antibody, antigen-binding fragment thereof and application thereof |
WO2020201828A1 (en) | 2019-04-05 | 2020-10-08 | Tauc3 Biologics Limited | Anti-tauc3 antibodies and uses thereof |
JP2023535024A (ja) | 2020-07-23 | 2023-08-15 | オター プロシーナ リミテッド | 抗aベータ抗体 |
TW202300517A (zh) | 2021-03-12 | 2023-01-01 | 美商美國禮來大藥廠 | 抗類澱粉β抗體及其用途 |
WO2022251048A1 (en) | 2021-05-24 | 2022-12-01 | Eli Lilly And Company | Anti-amyloid beta antibodies and uses thereof |
CN114591917B (zh) * | 2022-05-07 | 2022-09-02 | 北京第一生物化学药业有限公司 | 产生结合β-淀粉样蛋白的抗体的杂交瘤细胞及其用途 |
CN114591918B (zh) * | 2022-05-07 | 2022-07-26 | 北京第一生物化学药业有限公司 | 产生抗β-淀粉样蛋白抗体的杂交瘤细胞及其用途 |
KR102530956B1 (ko) * | 2022-09-08 | 2023-05-11 | 주식회사 알츠코리아 | 아밀로이드 베타 유래 에피토프를 유효성분으로 포함하는 알츠하이머성 치매 백신 조성물 및 이의 용도 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5811517A (en) * | 1992-01-27 | 1998-09-22 | Icos Corporation | ICAM-related protein variants |
PT994728E (pt) * | 1997-04-09 | 2008-11-11 | Intellect Neurosciences Inc | Anticorpos recombinantes específicos contra terminações beta-amilóide, codificação por adn e métodos de utilização destes |
US7179892B2 (en) | 2000-12-06 | 2007-02-20 | Neuralab Limited | Humanized antibodies that recognize beta amyloid peptide |
JP2002530122A (ja) * | 1998-11-25 | 2002-09-17 | サイオス インコーポレイテッド | アミロイド関連疾患の予防及び治療 |
EP1257584B2 (en) * | 2000-02-24 | 2013-03-06 | Washington University St. Louis | Humanized antibodies that sequester amyloid beta peptide |
AU2002239766B9 (en) * | 2000-11-03 | 2007-04-05 | The J. David Gladstone Institutes | Methods of treating disorders related to apoE |
WO2004029629A1 (en) * | 2002-09-27 | 2004-04-08 | Janssen Pharmaceutica N.V. | N-11 truncated amyloid-beta nomoclonal antibodies, compositions, methods and uses |
ITTO20020867A1 (it) * | 2002-10-08 | 2004-04-09 | Pro Cord Spa | Schienale di sedia. |
KR20050071564A (ko) * | 2002-10-09 | 2005-07-07 | 리나트 뉴로사이언스 코퍼레이션 | 아밀로이드 베타 펩티드에 대한 항체를 사용하여알츠하이머병을 치료하는 방법 및 그의 조성물 |
-
2007
- 2007-03-27 ES ES07727401T patent/ES2338179T3/es active Active
- 2007-03-27 SI SI200731503T patent/SI2177536T1/sl unknown
- 2007-03-27 UA UAA200810923A patent/UA94734C2/ru unknown
- 2007-03-27 US US12/294,438 patent/US8227576B2/en not_active Expired - Fee Related
- 2007-03-27 KR KR1020127016745A patent/KR20120093400A/ko not_active Application Discontinuation
- 2007-03-27 EA EA200801842A patent/EA015654B9/ru not_active IP Right Cessation
- 2007-03-27 NZ NZ571038A patent/NZ571038A/en not_active IP Right Cessation
- 2007-03-27 PT PT07727401T patent/PT1996621E/pt unknown
- 2007-03-27 AU AU2007233831A patent/AU2007233831B2/en not_active Ceased
- 2007-03-27 CN CN2007800124360A patent/CN101415729B/zh not_active Expired - Fee Related
- 2007-03-27 DK DK09178407.4T patent/DK2177536T3/da active
- 2007-03-27 KR KR1020087026640A patent/KR101263294B1/ko not_active IP Right Cessation
- 2007-03-27 JP JP2009502072A patent/JP5103466B2/ja not_active Expired - Fee Related
- 2007-03-27 SI SI200730173T patent/SI1996621T1/sl unknown
- 2007-03-27 AT AT07727401T patent/ATE451392T1/de active
- 2007-03-27 CA CA2647808A patent/CA2647808C/en not_active Expired - Fee Related
- 2007-03-27 DE DE602007003703T patent/DE602007003703D1/de active Active
- 2007-03-27 DK DK07727401.7T patent/DK1996621T3/da active
- 2007-03-27 BR BRPI0709246-6A patent/BRPI0709246A2/pt not_active IP Right Cessation
- 2007-03-27 CN CN201310338011.6A patent/CN103539857A/zh active Pending
- 2007-03-27 PL PL09178407T patent/PL2177536T3/pl unknown
- 2007-03-27 PT PT91784074T patent/PT2177536E/pt unknown
- 2007-03-27 EP EP09178407.4A patent/EP2177536B1/en active Active
- 2007-03-27 WO PCT/EP2007/052928 patent/WO2007113172A2/en active Application Filing
- 2007-03-27 PL PL07727401T patent/PL1996621T3/pl unknown
- 2007-03-27 MX MX2008012483A patent/MX2008012483A/es active IP Right Grant
- 2007-03-27 EP EP07727401A patent/EP1996621B1/en active Active
- 2007-03-27 ES ES09178407.4T patent/ES2484967T3/es active Active
- 2007-03-28 JO JO200788A patent/JO2576B1/en active
- 2007-03-28 PE PE2007000354A patent/PE20080181A1/es not_active Application Discontinuation
- 2007-03-28 TW TW096110663A patent/TWI385179B/zh not_active IP Right Cessation
- 2007-03-28 AR ARP070101295A patent/AR060332A1/es not_active Application Discontinuation
-
2008
- 2008-08-26 IL IL193695A patent/IL193695A/en not_active IP Right Cessation
- 2008-09-03 NO NO20083793A patent/NO20083793L/no not_active Application Discontinuation
- 2008-09-15 ZA ZA200807911A patent/ZA200807911B/xx unknown
- 2008-09-26 MY MYPI20083843A patent/MY149630A/en unknown
- 2008-10-07 CR CR10347A patent/CR10347A/es unknown
- 2008-10-15 MA MA31293A patent/MA30337B1/fr unknown
-
2009
- 2009-03-18 HK HK10104228.4A patent/HK1138015A1/xx not_active IP Right Cessation
- 2009-03-18 HK HK09102564.3A patent/HK1122311A1/xx not_active IP Right Cessation
-
2010
- 2010-03-01 CY CY20101100198T patent/CY1109877T1/el unknown
- 2010-03-02 HR HR20100115T patent/HRP20100115T1/hr unknown
-
2012
- 2012-06-08 US US13/491,810 patent/US9193784B2/en not_active Expired - Fee Related
-
2014
- 2014-06-30 HR HRP20140618TT patent/HRP20140618T1/hr unknown
-
2015
- 2015-10-13 US US14/881,428 patent/US20160024197A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL193695A0 (en) | Antibodies against amyloid-beta peptide | |
HRP20130320T1 (en) | Anti-myostatin antibodies | |
HRP20150176T1 (en) | Anti-myostatin antibodies | |
IL189579A0 (en) | Anti-myostatin antibodies | |
GB0615662D0 (en) | Antibody | |
EP2017283A4 (en) | Peptides | |
EP2101804A4 (en) | PRO-ANGIOGENIC PEPTIDES | |
GB0618748D0 (en) | Peptide | |
GB0605774D0 (en) | Peptide | |
IL197675A0 (en) | Peptides | |
GB0612443D0 (en) | Protein | |
GB0620304D0 (en) | Protein | |
GB0607376D0 (en) | Antibodies | |
GB0606276D0 (en) | Antibodies | |
GB0609921D0 (en) | Peptides | |
GB0625176D0 (en) | Peptides | |
GB0618512D0 (en) | Peptides | |
GB0609920D0 (en) | Peptides | |
GB0616971D0 (en) | Protein | |
GB0613471D0 (en) | Protein | |
GB0614683D0 (en) | Protein | |
GB0616970D0 (en) | Protein | |
GB0616969D0 (en) | Protein | |
GB0616968D0 (en) | Protein | |
GB0615655D0 (en) | Protein |